Oral recombinant human insulin - Rani Therapeutics
Latest Information Update: 28 May 2023
At a glance
- Originator Rani Therapeutics
- Class Antihyperglycaemics; Insulins; Pancreatic hormones; Recombinant fusion proteins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (PO)
- 21 May 2019 Preclinical development in Diabetes mellitus is ongoing in USA (Parenteral)
- 23 Mar 2019 Interim pharmacokinetic data from a preclinical trial in diabetes presented at the 101st Annual Meeting of the Endocrine Society (ENDO-2019)